Clinical trials - ain't they a bitch!?
Morgan Stanley said on Friday that AstraZeneca's cholesterol buster Crestor did not significantly reduce plaque in the carotid artery in a clinical trial comparing it to placebo.
Jami Rubin, an analyst for Morgan Stanley, drew her conclusions from an abstract of the highly awaited METEOR trial sponsored by AstraZeneca.
Specific data from the trial are slated to be presented on March 25 at the ACC in New Orleans.
The study, which compared Crestor to placebo, was designed to show whether the drug reduces plaque in the carotid artery in asymptomatic patients with high cholesterol deemed at low risk of heart disease.
Post a Comment